Rituximab in the treatment of pediatric small bowel transplant patients with posttransplant lymphoproliferative disorder unresponsive to standard treatment.
McGhee
W
W
Department of Pharmacy, Children's Hospital of Pittsburgh, Pittsburgh, Pennsylvania 15213, USA. mcGheew@chplink.chp.edu
Mazariegos
G V
GV
Sindhi
R
R
Abu-Elmagd
K
K
Reyes
J
J
D000293:Adolescent; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D058846:Antibodies, Monoclonal, Murine-Derived; D002648:Child; D006801:Humans; D007223:Infant; D007421:Intestine, Small / Q000637:transplantation*; D008232:Lymphoproliferative Disorders / Q000188:drug therapy*; D008297:Male; D011183:Postoperative Complications / Q000188:drug therapy* / Q000276:immunology; D012189:Retrospective Studies; D000069283:Rituximab; D014184:Transplantation, Homologous / Q000473:pathology*
D000911:Antibodies, Monoclonal; D058846:Antibodies, Monoclonal, Murine-Derived; D000069283:Rituximab